VT News

Akin Famewo

Ask VT AI
View News Summary
  • Gilead Sciences reports strong Q2 results, raises full-year guidance, and sees shares rise on the back of its HIV portfolio and new drug launches.
  • Lilly's oral weight loss pill trails rivals in efficacy, faces market delay due to tolerability concerns.
  • Crocs shares plunge due to declining Q3 sales, tariff impact, and shifting consumer behavior, leading the company to adjust its strategy to protect brand health and profitability.
20 hours
USA flag

United States Politics

Discover the latest news, candidates, 
and key topics of US politics

Latest News
Ask VT AI
View News Summary
  • Gilead Sciences reports strong Q2 results, raises full-year guidance, and sees shares rise on the back of its HIV portfolio and new drug launches.
  • Lilly's oral weight loss pill trails rivals in efficacy, faces market delay due to tolerability concerns.
  • Crocs shares plunge due to declining Q3 sales, tariff impact, and shifting consumer behavior, leading the company to adjust its strategy to protect brand health and profitability.
20 hours
USA flag

United States Politics

Discover the latest news, candidates, 
and key topics of US politics

Most Reported By
News from Akin Famewo

Top Topics

Trending in U.S.

World

Sport